Cancer Immunotherapy Market Size, Share, By Product Type (Monoclonal Antibodies, Immunomodulators, Checkpoint Inhibitors, Adoptive Cell Therapy, and Others), Cancer Type (Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Head & Neck Cancer, Prostat

Cancer immunotherapy represents a new and bright approach to cancer treatment, whereby one's immune system is manipulated to battle malignant cells. The increasing research in cancer immunotherapy is expected to propel market growth during the forecast period.

Cancer Immunotherapy Market Report Highlights:

• The cancer immunotherapy market size is projected to reach USD 530.2 billion by 2034.
• The market was valued at USD 158.5 billion in 2024.
• The market is expected to expand at a CAGR of 14.2% during the forecast period.
• North America holds the largest share in the market.
• Asia Pacific is expected to witness fast growth during the forecast period.
• By product type, the monoclonal antibodies segment is expected to lead the market during the forecast period.
• On the basis of cancer type, lung cancer is the most dominant segment in the market.
• Based on end-user, the market is being led by the hospitals segment.

Cancer Immunotherapy Market Key Highlights:

• In June 2024, a new phase 2 research started to examine a triple medication combination for pancreatic cancer. The University of Glasgow and the NHS Greater Glasgow and Clyde have initiated a mid-stage trial to test a new drug combination as a first-line treatment for patients with metastatic pancreatic cancer. The phase 2 PRIMUS-006 study, part of the Precision-Panc Platform, will evaluate Eli Lilly and Genentech's Gemzar (gemcitabine) in combination with Merck & Co's Keytruda (pembrolizumab), known as MSD outside the U.S. and Canada, and Immodulon Therapeutics' investigational IMM-101 in metastatic pancreatic ductal adenocarcinoma (PDAC).
• In April 2024, Hope beckons as the first homegrown cell therapy for cancer treatment is announced. President Droupadi Murmu introduced India's first indigenously developed CAR T-cell therapy for cancer treatment, calling it a "breakthrough" that will give humanity new hope in the fight against the disease. NexCAR19 CAR T-cell therapy is the country's first 'Made in India' cell therapy, and it will considerably reduce cancer treatment costs. This gene-based therapy, developed by the Indian Institute of Technology (IIT) Bombay and the Tata Memorial Centre, aims to cure several types of cancer.

Browse ∼37 market data tables and ∼39 figures through ∼167 slides and in-depth TOC on “Cancer Immunotherapy Market Size, Share, By Product Type (Monoclonal Antibodies, Immunomodulators, Checkpoint Inhibitors, Adoptive Cell Therapy, and Others), Cancer Type (Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Head & Neck Cancer, Prostate Cancer, and Others), End-User (Hospitals, Cancer Research Centers, and Others), and Region - Trends, Analysis and Forecast till 2034”

Cancer Immunotherapy Market Competitive Landscape:

The major players operating in the cancer immunotherapy market include Amgen, Inc., AstraZeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily And Company, F. Hoffmann-La Roche, Ltd., Pfizer, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, and Immunocore, Ltd.

Segmentation:

By Product Type:

• Monoclonal Antibodies
• Immunomodulators
• Checkpoint Inhibitors
• Adoptive Cell Therapy
• Others

By Cancer Type:

• Lung Cancer
• Colorectal Cancer
• Melanoma
• Breast Cancer
• Head & Neck Cancer
• Prostate Cancer
• Others

By End-User:

• Hospitals
• Cancer Research Centers
• Others

By Region:

North America

• U.S.
• Canada

Europe

• Germany
• U.K.
• France
• Russia
• Italy
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• Israel
• South Africa
• Rest of Middle East & Africa